不同方式内镜下治疗直肠小型神经内分泌肿瘤的临床价值评估

注册号:

Registration number:

ChiCTR2600118449 

最近更新日期:

Date of Last Refreshed on:

2026-02-05 16:14:52 

注册时间:

Date of Registration:

2026-02-05 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

不同方式内镜下治疗直肠小型神经内分泌肿瘤的临床价值评估

Public title:

Evaluation of the Clinical Value of Different Endoscopic Treatments for Small Rectal Neuroendocrine Tumors

注册题目简写:

English Acronym:

研究课题的正式科学名称:

不同方式内镜下治疗直肠小型神经内分泌肿瘤的临床价值评估

Scientific title:

Evaluation of the Clinical Value of Different Endoscopic Treatments for Small Rectal Neuroendocrine Tumors

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

邹德泓 

研究负责人:

文武 

Applicant:

Dehong Zou 

Study leader:

Wu Wen 

申请注册联系人电话:

Applicant telephone:

+86 183 0831 5296

研究负责人电话:

Study leader's
telephone:

+86 189 8062 3591

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zdhxhdoc@163.com

研究负责人电子邮件:

Study leader's E-mail:

wenwu2@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市庆云南街10号

研究负责人通讯地址:

四川省成都市庆云南街10号

Applicant address:

No. 10, Qingyun South Street, Chengdu City, Sichuan Province, China

Study leader's address:

No. 10, Qingyun South Street, Chengdu City, Sichuan Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都市第二人民医院

Applicant's institution:

Chengdu Second People's Hospital

研究负责人所在单位:

成都市第二人民医院

Affiliation of the Leader:

Chengdu Second People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[KY]PJ2025495

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

成都市第二人民医院医学伦理审查委员会

Name of the ethic committee:

Chengdu Second People's Hospital Medical Ethics Review Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2025-10-17 00:00:00

伦理委员会联系人:

陈乔

Contact Name of the ethic committee:

Qiao Chen

伦理委员会联系地址:

四川省成都市庆云南街10号

Contact Address of the ethic committee:

No. 10, Qingyun South Street, Chengdu City, Sichuan Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 138 0805 5402

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

成都市第二人民医院

Primary sponsor:

Chengdu Second People's Hospital

研究实施负责(组长)单位地址:

四川省成都市庆云南街10号

Primary sponsor's address:

No. 10, Qingyun South Street, Chengdu City, Sichuan Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

SiChuan

City:

Chengdu

单位(医院):

成都市第二人民医院

具体地址:

四川省成都市庆云南街10号

Institution
hospital:

Chengdu Second People's Hospital

Address:

No. 10, Qingyun South Street, Chengdu City, Sichuan Province, China

经费或物资来源:

成都市重点专科

Source(s) of funding:

Chengdu Key Medical Specialty​

研究疾病:

直肠神经内分泌肿瘤  

Target disease:

Rectal neuroendocrine tumor

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

通过比较内镜下钛夹辅助的黏膜下切除术(CA-ESMR)、套扎辅助内镜黏膜切除术(EMR-L)和内镜黏膜下剥离术(ESD)三种方法,评估其在治疗直肠小型神经内分泌肿瘤中的R0切除率、安全性及简捷性。  

Objectives of Study:

By comparing three methods—endoscopic titanium clip-assisted submucosal resection (CA-ESMR), ligation-assisted endoscopic mucosal resection (EMR-L), and endoscopic submucosal dissection (ESD)—the study evaluates their R0 resection rates, safety, and simplicity in treating small rectal neuroendocrine tumors.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 肿瘤侵犯肌层或有淋巴结转移; 2. 有严重心肺疾病或其他重大疾病不能耐受内镜治疗; 3. 妊娠或哺乳期妇女; 4. 有凝血功能障碍或正在服用抗凝药物。

Exclusion criteria:

1. Tumor invades the muscular layer or has lymph node metastasis; 2. Severe cardiopulmonary disease or other major conditions that contraindicate endoscopic treatment; 3. Pregnant or lactating women; 4. Coagulation disorders or current use of anticoagulant medications.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2029-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-02-09 00:00:00 To 2029-01-01 00:00:00

干预措施:

Interventions:

组别:

干预组1

样本量:

30

Group:

Intervention Group 1

Sample size:

干预措施:

CA-ESMR 钛夹辅助黏膜下切除术

干预措施代码:

Intervention:

CA-ESMR Titanium clip-assisted submucosal resection

Intervention code:

组别:

干预组2

样本量:

30

Group:

Intervention Group 2

Sample size:

干预措施:

EMR-L 套扎辅助内镜黏膜切除术

干预措施代码:

Intervention:

EMR-L Band ligation-assisted endoscopic mucosal resection

Intervention code:

组别:

对照组

样本量:

30

Group:

Control Group

Sample size:

干预措施:

ESD 内镜黏膜下剥离术

干预措施代码:

Intervention:

ESD Endoscopic submucosal dissection

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

成都市第二人民医院 

单位级别:

三甲 

Institution
hospital:

Chengdu Second People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

复发率

指标类型:

次要指标

Outcome:

recurrence rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

无病生存期

指标类型:

次要指标

Outcome:

Disease-free survival

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

安全性

指标类型:

次要指标

Outcome:

safety

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

器械使用复杂度

指标类型:

次要指标

Outcome:

Complexity of equipment usage

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

操作时间

指标类型:

次要指标

Outcome:

operation time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术花费

指标类型:

次要指标

Outcome:

surgical cost

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

R0切除率

指标类型:

主要指标

Outcome:

R0 resection rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

直肠肿瘤组织

组织:

Sample Name:

Rectal tumor tissue

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

课题组成员袁景使用随机序列法进行随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Yuan Jing, a member of the research team, used the random sequence method for randomization.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

患者被随机分配由于手术技术本质不同,手术团队无法设盲。为减少偏倚,本研究对患者设盲:所有患者在术前均被告知他们将接受‘微创手术’,并使用相同的麻醉和术前准备流程。主要结局由一位不参与患者围手术期管理的、经过培训的独立研究者在术后访视时进行评估,该评估者对患者的具体手术方式不知情。

Blinding:

Patients were randomly allocated. Because the surgical techniques differed fundamentally, the operating team could not be blinded. To minimize bias, patients were blinded: all were told pre-operatively that they would undergo "minimally invasive surgery" and received identical anaesthetic and pre-operative protocols. The primary outcome was assessed at the post-operative visit by a trained, independent investigator who was not involved in peri-operative care and remained unaware of each patient’s specific surgical procedure.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Do not share data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(Case Record Form, CRF)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-02-05 16:14:36